Who is sponsoring NCT00411879?

NCT00411879 is sponsored by University of Athens.

What condition does NCT00411879 study?

NCT00411879 studies Heart Arrest.

What drugs are being tested in NCT00411879?

Interventions: Vasopressin, Epinephrine, and Steroids, Placebo, Epinephrine, Placebo.

What is the status of NCT00411879?

NCT00411879 is currently COMPLETED.

Last reviewed 2016-01-08 · How we verify

Phase 2, Single-Center, Placebo-Controlled Study of the Effects of Combined Administration of Vasopressin, Methylprednisolone, and Epinephrine During Cardiopulmonary Resuscitation on Survival After Cardiac Arrest

NCT00411879 Phase 2 COMPLETED

A randomized controlled trial did not show benefit of vasopressin versus epinephrine in inhospital cardiac arrest. Preceding laboratory data suggest that combined vasopressin and epinephrine ensure long-term survival and neurologic recovery. Also, postresuscitation abnormalities mimic severe sepsis. The investigators hypothesized that combined vasopressin and epinephrine during cardiopulmonary resuscitation (CPR), and steroid supplementation during and after (when required) CPR may improve survival in cardiac arrest.

Details

Lead sponsor	University of Athens
Phase	Phase 2
Status	COMPLETED
Enrolment	100
Start date	2006-06
Completion	2007-04

Conditions

Heart Arrest

Interventions

Vasopressin, Epinephrine, and Steroids
Placebo, Epinephrine, Placebo

Primary outcomes

1) Return of Spontaneous Circulation for > 15 min and 2) Survival to discharge either to home or to a rehabilitation facility. — 60 days (actual)

Countries

Greece